MMJ PhytoTech’s vision is to become a leading player in the global medical cannabis market, through the development & commercialisation of cannabinoid based therapeutic products and as a grower and supplier of unique strains of cannabis to treat a variety of clinical indications in established, existing and newly regulated markets.
MMJ PhytoTech’s strategy is based on establishing a vertically integrated “Farm to Pharma” business model, building operations across all parts of the supply chain, including growing operations, development of cannabinoids based drug-products, production and commercialisation of medical cannabis products and distribution in regulated markets worldwide.
The Company has two main focuses: Therapeutics and Agro-Medical
The Company is developing cannabinoids based drug-products for a variety of highly potential clinical indications utilising state-of-the-art, proprietary drug delivery technologies and formulations.
The Company is establishing strategic alliances with the aim to acquire sophisticated genetic Good Manufacturing Practice (GMP) strains and plants and to secure near term revenues streams from growing operations, capitalising on the growth of the regulated Canadian and US medical cannabis markets.
MMJ PhytoTech Limited is a Medical Cannabis company, which aims to commercialise Medical Grade Cannabis (MGC) and high potential cannabis based therapeutics products to the rapidly growing international market with regulated medical cannabis laws. The Company operates three subsidiaries with operations across the entire Medical Cannabis value chain, encompassing the Company’s “Farm to Pharma” strategy.
The newly merged entity MMJ-PhytoTech now comprises of the following operating units:
United Greeneries is the Canadian based subsidiary of MMJ PhytoTech. It currently owns two state-of-the-art medical grade cannabis cultivation facilities, the Duncan Facility and the Lucky Lake Facility, with a combined footprint of 78,000ft².
The Duncan Facility and Laboratory is a 16,000ft² building with a level-8 vault, 3 bays and close to 10,000ft² of cultivation area. The facility is completely built out and is located on Vancouver Island in Duncan, British Columbia. Duncan has an integrated fully compliant QA/QC (Quality Assurance and Quality Control) laboratory for internal testing as well as third party testing services as required by Health Canada. The Duncan Facility will be able to produce up to 700kg of Medical Grade Cannabis per annum once granted an MMPR (Marijuana for Medical Purposes Regulation) production license, which the Company expects to occur in the second half of 2015.
AgriChem Analytical is part of the United Greeneries operation. It provides state-of-the-art biochemical quality control testing and Cannabinoid analytics, as required under the Canadian MMPR (Marijuana for Medical Purposes Regulation). AgriChem Analytical is directly integrated with United Greeneries’ Duncan cultivation facility. These services play an essential role in furthering Cannabinoid drug development and continuous compliance with MMPR quality requirements.
Satipharm is the Swiss subsidiary of MMJ PhytoTech developing cannabis based pharmaceutical, nutraceutical and cosmetic products for a variety of conditions. Satipharm, together with its cannabis extraction manufacturing partners, has developed a proprietary gastro-resistant Cannabidiol (CBD) pill. The pill will be legally sold as a dietary supplement over the counter in Europe.
PhytoTech Therapeutics is the Israeli based subsidiary of MMJ PhytoTech focusing on the development of drug-products for administering cannabinoids to treat various medical conditions. The company has entered into an exclusive research and licensing agreement with Yissum Research Development Company, the prestigious research development and technology transfer company of the Hebrew University of Jerusalem.
PhytoTech Therapeutics is developing a number of products including an oral capsule and buccal patch containing a combination of Cannabidiol (CBD) and Tetrahydrocannabinol (THC) for treating various clinical indications. The first product aimed to enter shortly into clinical studies is an oral capsule for the treatment of pain and spasticity in Multiple Sclerosis patients.
Non-Executive Chairman / Independent
LLB, BComm, MAppFin, FFin
Mr Wall was appointed as Non-Executive Chairman of the Company on 14 August 2014.
Mr Wall is a corporate lawyer and has been a Partner at Steinepreis Paganin (Perth based corporate law firm) since July 2005. Mr Wall graduated from the University of Western Australia in 1998 with a Bachelor of Laws and Bachelor of Commerce (Finance). He has also completed a Masters of Applied Finance and Investment with FINSIA.
Mr Wall has a wide range of experience in all forms of commercial and corporate law, with a particular focus on resources (hard rock and oil/gas), equity capital markets and mergers and acquisitions. He also has significant experience in dealing in cross border transactions.
Managing Director / Non-Independent
Mr Gedeon was appointed as Managing Director of the Company on 27 July 2015.
Mr. Gedeon, a former Officer in the German Navy, holds a degree in Educational Science from the University of Federal Armed Forces Munich. He is an experienced business man with proven expertise in large-scale and HR intensive projects. His previous areas of work include media production, the food industry, horticulture and commercial construction. As the founder of MMJ, Mr. Gedeon currently oversees the global expansion strategy of the MMJ group and is the designated Managing Director of MMJ/PYL post-merger.
Non Executive Director / Independent
BBus., DipEd., PGDipBus., MCom., FFin, CPA, MAICD, ACIS/ACSA
Mr Willesee was appointed as Non-Executive Director of the Company on 21 October 2014.
Mr Willesee is an experienced company director with a broad range of skills and experience in strategy, company development, corporate governance, company public listings, merger and acquisition transactions and corporate finance.
He has considerable experience with ASX listed companies and has been involved with many successful ventures from early stage through to large capital development projects. He holds formal qualifications in economics, finance, accounting, education and governance. He is a Fellow of the Financial Services Institute of Australasia, a Member of the Australian Institute of Company Directors, a Member of CPA Australia and a Chartered Secretary.
Non-Executive Director / Independent
Mr Bednar was appointed as Non-Executive Director of the Company on 27 July 2015.
Mr. Bednar is a Chartered Accountant with more than 18 years of direct professional experience in the financial and regulatory management of companies listed on the Toronto Stock Exchange, TSX Venture Exchange, American Stock Exchange and ASX.
He is currently the CFO and director of Canacol Energy Ltd., a Colombian focused oil and gas exploration and production company with an enterprise value of approximately US$650 million. Mr. Bednar has been the past CFO of several international oil and gas E&P companies, most notably the founding Chief Financial Officer of Pan Orient Energy Corp, a South East Asia exploration company, who during his tenure grew organically to operate 15,000 bbl/d and a market cap of $700 million. He has previously sat on the board of directors of several internationally focused E&P companies, including being the past Chairman of Gallic Energy Ltd.
Mr. Bednar holds a Bachelor of Commerce degree from the University of Saskatchewan.
BCom., GradDipACG, AGIA, ACIS
Miss Dale was appointed as Company Secretary of the Company on 1 February 2015.
Ms Dale has a broad range of experience in company administration and corporate governance having held positions as non-executive director and/or company secretary for a number of ASX listed public companies across a range of industries. Ms Dale has completed a Bachelor of Commerce (Accounting and Finance) and a Graduate Diploma of Applied Corporate Governance and is an Associate Member of both the Institute of Chartered Secretaries and Administrators and the Governance Institute of Australia.
Dr. Daphna Heffetz
Chief Executive Officer, PhytoTech Therapeutics Limited
Ms Heffetz was appointed as Chief Executive Officer of the Company on 28 January 2015.
Dr Heffetz’s has over 20 years’ experience in establishing and growing Biotech and Medtech technology based companies. Her most recent position was Chief Executive Officer with Alon MedTech Ventures, an Israeli medical device and technology accelerator.
In 2000 she founded TransPharma Medical, a specialty pharmaceutical company, where she remained as CEO and Director of the Board until 2012. TransPharma became one of the most promising active transdermal drug delivery companies in the world. During her time at TransPharma she raised US$34 million in three financing rounds from leading Israeli and International venture capital funds and brought over US$50 million from collaborations with world leading pharmaceutical companies.
Dr Daphna Heffetz holds M.Sc and Ph.D degrees in Biochemistry and a Post-Doctoral Fellow in molecular biology from the Weizmann Institute of Science.
Our Company has adopted comprehensive systems of control and accountability as the basis for the administration of corporate governance. The Board is committed to administering the policies and procedures with openness and integrity, pursuing the true spirit of corporate governance commensurate with the Company's needs.
To the extent applicable, our Company has adopted The Corporate Governance Principles and Recommendations (3rd Edition)
as published by ASX Corporate Governance Council (Recommendations
You can download a copy of the Company's Corporate Governance Plan and Constitution here